Effect of the XIAP Inhibitor Embelin on TRAIL-Induced Apoptosis of Pancreatic Cancer Cells

Journal of Surgical Research

Volumn 142, Issue 2, 2007, Pages 281-286

  Mori, Tomohiko ^a   Doi, Ryuichiro ^a   Kida, Atsushi ^a   Nagai, Kazuyuki ^a   Kami, Kazuhiro ^a   Ito, Daisuke ^a   Toyoda, Eiji ^a   Kawaguchi, Yoshiya ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

apoptosis; caspase; pancreatic neoplasm; Smac; XIAP

Indexed keywords

EMBELIN; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

APOPTOSIS; BENZOQUINONES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; POLY(ADP-RIBOSE) POLYMERASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34548662911     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.03.068     Document Type: Article

References (21)

1. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10 (2003) 66
2. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 (2003) 8628
3. Mori T., Doi R., Toyoda E., et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 138 (2005) 71
4. Fulda S., Wick W., Weller M., et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8 (2002) 808
5. Yang L., Mashima T., Sato S., et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63 (2003) 831
6. Arnt C.R., Chiorean M.V., Heldebrant M.P., et al. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277 (2002) 44236
7. Pei Z., Chu L., Zou W., et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39 (2004) 1371
8. Zhang X., Jin T.G., Yang H., et al. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64 (2004) 7086
9. Poulaki V., Mitsiades C.S., Kotoula V., et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 161 (2002) 643
10. Nam S.Y., Jung G.A., Hur G.C., et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94 (2003) 1066
11. Summerton J., Stein D., Huang S.B., et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7 (1997) 63
12. Giles R.V., Spiller D.G., Clark R.E., et al. Antisense morpholino oligonucleotide analog induces mis-splicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev 9 (1999) 213
13. Ghosh C., Stein D., Weller D., et al. Evaluation of antisense mechanisms of action. Methods Enzymol 313 (2000) 135
14. Iversen P.L., Arora V., Acker A.J., et al. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9 (2003) 2510
15. Nikolovska-Coleska Z., Xu L., Hu Z., et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47 (2004) 2430
16. Holcik M., Gibson H., and Korneluk R.G. XIAP: Apoptotic brake and promising therapeutic target. Apoptosis 6 (2001) 253
17. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190
18. Kinoshita H., Yoshikawa H., Shiiki K., et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 88 (2000) 986
19. Vignati S., Codegoni A., Polato F., et al. TRAIL activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs. Eur J Cancer 38 (2002) 177
20. Wajant H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 3 (2003) 124
21. Xiao C.W., Yan X., Li Y., et al. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappa B-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 144 (2003) 623